We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

XOMA Corp (XOMAP) 8.625% Series A Cumulative Perpetual Pref

Sell:$25.30 Buy:$26.80 Change: $0.04 (0.15%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.30
Buy:$26.80
Change: $0.04 (0.15%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.30
Buy:$26.80
Change: $0.04 (0.15%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Contact details

Address:
2200 Powell Street, Suite 310
EMERYVILLE
94608
United States
Telephone:
+1 (510) 2047239
Website:
https://www.xoma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XOMAP
ISIN:
US98419J3059
Market cap:
$297.63 million
Shares in issue:
11.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Owen Hughes
    Chief Executive Officer, Director
  • Thomas Burns
    Chief Financial Officer, Senior Vice President - Finance
  • Bradley Sitko
    Chief Investment Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.